Meat processors hamper Zilmax study; Biofarma owners embark on stake sale;

@FiercePharma: Daiichi Sankyo sells off Ranbaxy's problems to Sun Pharma - FiercePharmaManufacturing. More | Follow @FiercePharma

@TracyStaton: FiercePharma's best-read marketing story: Sanofi aims for outcomes with new Chief Patient Officer. Article | Follow @TracyStaton

@EricPFierce: Daniel Fabricant leaves FDA where he regulated dietary supplements, returning to its lobbying group NPA as CEO. News via NutraIngredients-USA | Follow @EricPFierce

@CarlyHFierce: Teva entreats SCOTUS to block Copaxone generics till patent case wraps. Story | Follow @CarlyHFierce

> Merck ($MRK) wants to test controversial Zilmax on 240,000 U.S. cattle to prove its safety, but meat processors won't take animals fed with the additive, leaving feedlot owners reluctant to participate. Report

> Owners of Turkish company Biofarma Pharmaceutical have hired Goldman Sachs to begin the process of selling a stake in the drugmaker. News

> The Affordable Care Act has triggered double-digit increases in demand for pharmaceuticals, new data suggests. More

> McKesson ($MCK) says shareholders in its takeover target Celesio can tender their shares for an additional two-week period. News

> Almost a third of patients never fill the prescriptions for medicines they're told to take, a Canadian study has found. Report (sub. req.)

Medical Device News

@FierceMedDev: JenaValve pockets another $10M as it vies with Medtronic, Edwards. Story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Merck KGaA signs on to sell Auxogyn's IVF test. Article | Follow @VarunSaxena2

@EmilyWFierce: Electrical epidural stimulation helped four paralyzed men regain use of their lower limbs. More | Follow @EmilyWFierce

@MichaelGFierce: ICYMI: The year in nanotech drug delivery. Report from FierceDrugDelivery | Follow @MichaelGFierce

> Daktari Diagnostics brings in $13M to fund its HIV test. News

> Deerfield unveils a $1.6B new fund as med tech VC lags. Story

> Sequent bags $20M to get its aneurysm tech on the U.S. market. More

Biotech News

@FierceBiotech: Lilly preps a PhIII study as breast cancer drug race heats up. Story | Follow @FierceBiotech

@JohnCFierce: Versant gambles $12M on Swiss PI3K/mTOR cancer drug upstart--Piqur in Basel. Article | Follow @JohnCFierce

@DamianFierce: Here's FierceBiotech's look at every drug developer IPO from the first quarter. Report | Follow @DamianFierce

@EmilyMFierce: Study: Fewer clinical trials, less animal research conducted on diseases of the poor. More from FierceBiotech Research | Follow @EmilyMFierce

> Deerfield eyeing new biotech investments after launching $1.6B fund. Story

> Alkermes hits PhIII goal line with 'blockbuster' long-acting schizophrenia drug. More

> TetraLogic bags lymphoma therapy in $13M buyout. Item

Biotech Research News

> Lilly, Pfizer partner with Lieber Institute on brain research. Item

> Daiichi Sankyo, UCSF strike deal to combat neurodegeneration. Story

> Vitamin B-3 could slow progression of muscle-wasting disorder. Article

> Caffeine-based compound targets tau deposits in Alzheimer's. More

> Study: Fewer clinical trials, less animal research conducted on diseases of the poor. News

> Breast cancer gene BRCA1 linked to brain development. Report

Pharma Manufacturing News

> Daiichi Sankyo sells off Ranbaxy's problems to Sun Pharma. Report

> UPM putting plant it bought from Pfizer to more use. News

> Lilly well-positioned with track-and-trace deadlines advancing. Article

> FDA is adding inspectors in China but for now it has only two. Story

> China's WuXi invests in edible anti-counterfeiting tech. More

> GSK logistics program improves on-time delivery to 90%. Item

And Finally... A new study suggests a link between the use of antidepressants during pregnancy and a higher risk of premature birth. Report (sub. req.)

Suggested Articles

Bluebird Bio has overcome a manufacturing hiccup that looked like it would delay its gene therapy launch in Europe until next year.

Lilly's top U.S. executive is on his way out. Enrique Conterno, who also heads up Lilly's global diabetes business, will step down at year's end.

GlaxoSmithKline, Pfizer, Sanofi and Boehringer Ingelheim are facing lawsuit claims that they failed to test for possible carcinogens in Zantac.